240 results on '"Gerloni, Valeria"'
Search Results
2. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
Catalog
Books, media, physical & digital resources
3. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial
4. Correction to: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
5. The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
6. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
7. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
8. Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
9. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences
10. Pachydermodactyly
11. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea)
12. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis
13. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
14. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
15. Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial
16. Serum calprotectin (S100A8/9), clinical and ultrasound assessment in patients with juvenile idiopathic arthritis
17. Skin Manifestations Induced by TNF-Alpha Inhibitors in Juvenile Idiopathic Arthritis
18. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
19. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score
20. Adalimumub with or without Methotrexate in juvenile rheumatoid arthritis
21. Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study
22. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) (vol 17, 66, 2019): Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) (Pediatr Rheumatol Online J (2019) 17 (66) DOI: 10.1186/s12969-019-0345-2)
23. Chapter 18 TNF-Inhibitors in Pediatric Rheumatology
24. Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis
25. Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.: 1692
26. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)
27. Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial
28. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis
29. Additional file 1: of Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
30. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis
31. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors
32. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement
33. Localized Scleroderma in Childhood Is Not Just a Skin Disease
34. A Randomized, Double-Blind Clinical Trial of Two Doses of Meloxicam Compared With Naproxen in Children With Juvenile Idiopathic Arthritis: Short- and Long-Term Efficacy and Safety Results
35. Efficacy of Repeated Intravenous Infusions of an Anti–Tumor Necrosis Factor α Monoclonal Antibody, Infliximab, in Persistently Active, Refractory Juvenile Idiopathic Arthritis: Results of an Open-Label Prospective Study
36. Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
37. A Randomized Trial of Parenteral Methotrexate Comparing an Intermediate Dose With a Higher Dose in Children With Juvenile Idiopathic Arthritis Who Failed to Respond to Standard Doses of Methotrexate
38. Assessment of Damage in Juvenile-Onset Systemic Lupus Erythematosus: A Multicenter Cohort Study
39. AB1040 PEDIATRIC SJöGREN SYNDROME: A MONOCENTER CASE SERIES
40. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study
41. Biologics for the Treatment of Juvenile Idiopathic Arthritis
42. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial
43. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
44. Additional file 1: of Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
45. Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study.
46. Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA)
47. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
48. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
49. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis : An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative
50. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.